Company intelligence / Profile preview

Nobio

Petah Tikva, Central District, Israelnobio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nobio has developed a proprietary nanoparticle technology that provides long-term antibacterial and antiviral protection to surfaces in medical, dental, and consumer products. The company has commercialized some solutions in the dental field and continues to develop additional applications. Their approach aims to reduce healthcare-associated infections by making frequently touched or used items inhospitable to microbes indefinitely.

Therapeutic areas: Infectious Diseases
Modalities: Antimicrobial materials (nanoparticle-based)surface coatings for medical and dental devices/products
Industry: Chemicals & Materials

Drug pipeline

1 asset

Infinix

Commercial

Indications: Dental caries

Beyond the preview

Go deeper on Nobio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nobio.

Explore the full profile